PubRank

J M Lange

Author PubWeight™ 230.87‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992 10.25
2 Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol 1989 8.32
3 A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 1998 7.00
4 Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet 1986 4.54
5 Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992 4.21
6 Association between biological properties of human immunodeficiency virus variants and risk for AIDS and AIDS mortality. Lancet 1989 4.19
7 Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med 2001 3.74
8 Increased cell division but not thymic dysfunction rapidly affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat Med 2000 3.70
9 Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest 1988 3.59
10 Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) 1986 3.27
11 Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection. J Infect Dis 1992 3.16
12 Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. Br Med J (Clin Res Ed) 1986 2.75
13 Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998 2.67
14 Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 1990 2.50
15 Effect of zidovudine on serum human immunodeficiency virus antigen levels in symptom-free subjects. Lancet 1988 2.38
16 Antigenemia and antibody titers to core and envelope antigens in AIDS, AIDS-related complex, and subclinical human immunodeficiency virus infection. J Infect Dis 1987 2.17
17 Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000 2.14
18 Protection against sexually transmitted diseases by granting sex workers in Thailand the choice of using the male or female condom: results from a randomized controlled trial. AIDS 1998 2.14
19 Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1-infected patients on potent antiretroviral therapy. AIDS 1999 2.09
20 Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. J Infect Dis 1988 2.06
21 The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992 2.06
22 High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001 2.03
23 Risk of AIDS related complex and AIDS in homosexual men with persistent HIV antigenaemia. Br Med J (Clin Res Ed) 1987 2.02
24 Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998 1.88
25 Ongoing HIV dissemination during HAART. Nat Med 1999 1.85
26 Predictors of rapid progression to AIDS in HIV-1 seroconverters. AIDS 1993 1.85
27 Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 2001 1.81
28 OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion. J Clin Immunol 2001 1.75
29 Increasing cerebrospinal fluid chemokine concentrations despite undetectable cerebrospinal fluid HIV RNA in HIV-1-infected patients receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2000 1.68
30 Response to cytarabine in progressive multifocal leucoencephalopathy in AIDS. Lancet 1991 1.62
31 The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons. J Infect Dis 2001 1.62
32 Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999 1.61
33 Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1993 1.56
34 The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000 1.56
35 Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis. Clin Infect Dis 1997 1.51
36 HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS 1992 1.47
37 Slower decline of plasma HIV-1 RNA following highly suppressive antiretroviral therapy in primary compared with chronic infection. AIDS 2000 1.47
38 Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains. AIDS 2001 1.42
39 Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1)-infected men. J Clin Immunol 1990 1.42
40 Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. BMJ 1989 1.39
41 [Primary HIV-infection: infectious mononucleosis-like presentation with treatment options]. Ned Tijdschr Geneeskd 1999 1.39
42 [Virological evaluation of treating HIV-infected patients with (combinations of) antiretroviral drugs at the Amsterdam Academic Medical Center, 1996/'97]. Ned Tijdschr Geneeskd 1998 1.39
43 Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals. J Acquir Immune Defic Syndr 2001 1.37
44 The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999 1.36
45 Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS 1998 1.34
46 Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999 1.32
47 Antiretroviral drugs and the central nervous system. AIDS 1998 1.28
48 Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999 1.28
49 Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS 1998 1.28
50 Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000 1.26
51 Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2001 1.24
52 Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci U S A 1996 1.22
53 Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy. AIDS 1998 1.21
54 Decline in CD4+ cell numbers reflects increase in HIV-1 replication. AIDS Res Hum Retroviruses 1988 1.21
55 Herpes zoster, immunological deterioration and disease progression in HIV-1 infection. AIDS 1995 1.20
56 HTLV-III/LAV infection in nine children infected by a single plasma donor: clinical outcome and recognition patterns of viral proteins. J Infect Dis 1986 1.20
57 Presentation and course of AIDS dementia complex: 10 years of follow-up in Amsterdam, The Netherlands. AIDS 1993 1.16
58 Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 1999 1.12
59 Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment. AIDS 1997 1.11
60 Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1999 1.08
61 Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group. J Virol 1996 1.08
62 Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 2001 1.07
63 Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1998 1.06
64 Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. J Infect Dis 1996 1.05
65 Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. J Med Virol 1990 1.05
66 Viral phenotype and T cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. J Infect Dis 1993 1.04
67 HIV-related morbidity and mortality in sub-Saharan Africa: opportunities for prevention. AIDS 1993 1.04
68 Herpes simplex virus type 2 and other genital ulcerative infections as a risk factor for HIV-1 acquisition. Genitourin Med 1990 1.04
69 Failure to maintain high-dose treatment regimens during long-term use of zidovudine in patients with symptomatic human immunodeficiency virus type 1 infection. Genitourin Med 1990 1.04
70 Foscarnet and penile ulceration. Lancet 1990 1.04
71 Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group. AIDS 1999 1.04
72 Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs. AIDS 2000 1.03
73 Analysis of the antigen- and mitogen-induced differentiation of B lymphocytes from asymptomatic human immunodeficiency virus-seropositive male homosexuals. Discrepancy between T cell-dependent and T cell-independent activation. J Immunol 1987 1.02
74 Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. AIDS 2001 1.01
75 A retrospective, cohort-based survey of patients using twice-daily indinavir + ritonavir combinations: pharmacokinetics, safety, and efficacy. J Acquir Immune Defic Syndr 2001 1.00
76 Pathogenesis of HIV and its implications for serodiagnosis and monitoring of antiviral therapy. J Virol Methods 1987 0.99
77 Antibody response to viral proteins U (vpu) and R (vpr) in HIV-1-infected individuals. J Acquir Immune Defic Syndr 1990 0.99
78 Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. Clin Infect Dis 2001 0.99
79 Autoimmunity against blood cells in human immunodeficiency-virus (HIV) infection. Br J Haematol 1987 0.99
80 Value of different assays for detection of human cytomegalovirus (HCMV) in predicting the development of HCMV disease in human immunodeficiency virus-infected patients. J Clin Microbiol 2000 0.98
81 Improvement of chronic diarrhoea in patients with advanced HIV-1 infection during potent antiretroviral therapy. AIDS 1998 0.98
82 Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure. Antivir Ther 1996 0.97
83 Appearance of predictors of disease progression in relation to the development of AIDS. AIDS 1989 0.97
84 The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS 1998 0.96
85 Persistent human immunodeficiency virus type 1 antigenemia in children correlates with disease progression. Pediatrics 1988 0.96
86 Pharmacokinetic profiles of nevirapine and indinavir in various fractions of seminal plasma. Antimicrob Agents Chemother 2001 0.95
87 High-dose interferon-alpha2a exerts potent activity against human immunodeficiency virus type 1 not associated with antitumor activity in subjects with Kaposi's sarcoma. J Infect Dis 1997 0.95
88 Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals. AIDS 1998 0.94
89 Low number of functionally active B lymphocytes in the peripheral blood of HIV-1-seropositive individuals with low p24-specific serum antibody titers. AIDS 1991 0.93
90 Pharmacokinetics of stavudine and didanosine coadministered with nelfinavir in human immunodeficiency virus-exposed neonates. Antimicrob Agents Chemother 2001 0.93
91 Contribution of antibody response to recombinant HIV-1 gene-encoded products nef, rev, tat, and protease in predicting development of AIDS in HIV-1-infected individuals. J Acquir Immune Defic Syndr 1991 0.92
92 Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study. AIDS 2000 0.91
93 Therapeutic immune reconstitution in HIV-1-infected children is independent of their age and pretreatment immune status. AIDS 2001 0.91
94 Resumption of HIV antigen production during continuous zidovudine treatment. Lancet 1988 0.91
95 Treatment of HIV infection. Tolerability of commonly used antiretroviral agents. Drug Saf 1996 0.90
96 High-dose nevirapine in previously untreated human immunodeficiency virus type 1-infected persons does not result in sustained suppression of viral replication. J Infect Dis 1997 0.89
97 Dose-finding study of a once-daily indinavir/ritonavir regimen. J Acquir Immune Defic Syndr 2000 0.89
98 Toxicity and drug exposure in a quadruple drug regimen in HIV-1 infected patients participating in the ADAM study. AIDS 2000 0.89
99 Antibody response to the viral negative factor (nef) in HIV-1 infection: a correlate of levels of HIV-1 expression. AIDS 1989 0.88
100 Boost for vaginal microbicides against HIV. Lancet 1993 0.88
101 Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression. Clin Exp Immunol 1996 0.88
102 Persistence of human immunodeficiency virus antigenemia in patients with the acquired immunodeficiency syndrome treated with a reverse transcriptase inhibitor, suramin. Ten-patient case-control study. Arch Intern Med 1988 0.88
103 Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr Hum Retrovirol 1997 0.88
104 Human immunodeficiency virus exanthem. J Am Acad Dermatol 1990 0.87
105 Dehydroepiandrosterone as predictor for progression to AIDS in asymptomatic human immunodeficiency virus-infected men. J Infect Dis 1992 0.87
106 Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. J Infect Dis 1999 0.87
107 Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1999 0.86
108 Cellular and humoral immunity in various cohorts of male homosexuals in relation to infection with human immunodeficiency virus. Neth J Med 1989 0.86
109 Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine. Ther Drug Monit 2001 0.86
110 Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations. AIDS Res Hum Retroviruses 2000 0.86
111 Concentrations of human immunodeficiency virus type 1 (HIV-1) RNA in cerebrospinal fluid after antiretroviral treatment initiated during primary HIV-1 infection. Clin Infect Dis 2001 0.85
112 New antiretrovirals and new combinations. AIDS 1998 0.85
113 Potassium prevents death from strokes in hypertensive rats without lowering blood pressure. J Hypertens Suppl 1984 0.84
114 Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA. J Clin Invest 2000 0.84
115 Syngeneic leukocytes together with suramin failed to improve immunodeficiency in a case of transfusion-associated AIDS after syngeneic bone marrow transplantation. Blood 1988 0.84
116 Low antigenicity of HIV-1 rev: rev-specific antibody response of limited value as correlate of rev gene expression and disease progression. AIDS Res Hum Retroviruses 1989 0.84
117 A study of the reliability, validity and responsiveness of the HIV overview of problems evaluation system (HOPES) in assessing the quality of life of patients with AIDS and symptomatic HIV infection. Qual Life Res 1996 0.83
118 Lack of efficacy of low dose oral interferon alfa in symptomatic HIV-1 infection: a randomised, double blind, placebo controlled trial. Sex Transm Infect 1998 0.83
119 [LAV/HTLV-III infection after a one-time sexual contact with an AIDS patient]. Ned Tijdschr Geneeskd 1985 0.82
120 Decline of HIV antigen levels in cerebrospinal fluid during treatment with low-dose zidovudine. AIDS 1988 0.82
121 Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine. J Neuroimmunol 2000 0.82
122 Saliva as an alternative body fluid for therapeutic drug monitoring of the nonnucleoside reverse transcription inhibitor nevirapine. Ther Drug Monit 2001 0.82
123 Consensus symposium on combined antiviral therapy. International Society for Antiviral Research and the National Institutes of Allergy and Infectious Diseases. Antiviral Res 1996 0.82
124 A randomized, dose-finding study with didanosine plus stavudine versus didanosine alone in antiviral-naive, HIV-infected Thai patients. AIDS 2000 0.81
125 Complications of varicella zoster virus reactivation in HIV-infected homosexual men. AIDS 1996 0.81
126 Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine. Antivir Ther 1997 0.81
127 AIDS dementia complex and didanosine. Lancet 1994 0.80
128 Amprolium for coccidiosis in AIDS. Lancet 1984 0.80
129 Summary of the international consensus symposium on management of HIV, CMV and hepatitis virus infections. Antiviral Res 1998 0.80
130 Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects. Antiviral Res 1990 0.80
131 High-K diets reduce brain haemorrhage and infarcts, death rate and mesenteric arteriolar hypertrophy in stroke-prone spontaneously hypertensive rats. J Hypertens Suppl 1986 0.80
132 Clinical, virological and immunological features of primary HIV-1 infection. Genitourin Med 1991 0.80
133 A randomized, double-blind trial of half versus standard dose of zidovudine plus zalcitabine in Thai HIV-1-infected patients (study HIV-NAT 001). HIV Netherlands Australia Thailand Research Collaboration. AIDS 2000 0.80
134 T-cell progenitor function during progressive human immunodeficiency virus-1 infection and after antiretroviral therapy. Blood 2000 0.80
135 The ADAM study continued: maintenance therapy after 50 weeks of induction therapy. AIDS 2001 0.79
136 Adequacy of peritoneal dialysis and the importance of preserving residual renal function. Nephrol Dial Transplant 2006 0.79
137 Temporary increase in serum beta 2-microglobulin during treatment with interferon-alpha for AIDS-associated Kaposi's sarcoma. AIDS 1990 0.79
138 Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. J Clin Invest 1997 0.79
139 Autoantibodies against peripheral blood cells appear early in HIV infection and their prevalence increases with disease progression. Clin Exp Immunol 1990 0.79
140 Pathogenicity and diversity of HIV and implications for clinical management: a review. J Acquir Immune Defic Syndr 1994 0.78
141 Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine. AIDS 2001 0.78
142 Immunization with recombinant p17/p24:Ty virus-like particles in human immunodeficiency virus-infected persons. J Infect Dis 1996 0.78
143 Quality of life in maintenance vs prolonged induction therapy for HIV. JAMA 2000 0.78
144 A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. J Acquir Immune Defic Syndr 2001 0.78
145 T cell expansions in lymph nodes and peripheral blood in HIV-1-infected individuals: effect of antiretroviral therapy. AIDS 2001 0.78
146 An experimental investigation of the effect of a justice violation on pain experience and expression among individuals with high and low just world beliefs. Eur J Pain 2013 0.78
147 Pyrimethamine alone as maintenance therapy for central nervous system toxoplasmosis in 38 patients with AIDS. J Acquir Immune Defic Syndr 1992 0.78
148 Serum p24 antigen levels in untreated and zidovudine-treated HIV-1 infected subjects. Neth J Med 1990 0.78
149 Influenza-like syndrome in homosexual men: a prospective diagnostic study. J R Coll Gen Pract 1988 0.78
150 Differences in clinical course in zidovudine-treated asymptomatic HIV-infected men associated with T-cell function at intake. AIDS 1991 0.78
151 Disseminated cat-scratch disease in a patient with AIDS. AIDS 1989 0.78
152 High potassium diets reduce macrophage adherence to the vascular wall in stroke-prone spontaneously hypertensive rats. J Vasc Res 1996 0.77
153 [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection]. Ned Tijdschr Geneeskd 2006 0.77
154 Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995 0.77
155 Frequent use of menfegol spermicidal vaginal foaming tablets associated with a high incidence of genital lesions. J Infect Dis 1995 0.77
156 High potassium diets greatly increase growth-inhibiting agents in aortas of hypertensive rats. Hypertension 1992 0.77
157 Once-daily indinavir plus ritonavir: preliminary results of the PIPO study. AIDS 2000 0.77
158 Can the course of high dose cotrimoxazole for Pneumocystis carinii pneumonia in AIDS be shorter? A possible solution to the problem of cotrimoxazole toxicity. J Intern Med 1990 0.77
159 Durable HIV-1 suppression with indinavir after failing lamivudine-containing double nucleoside therapy: a randomized controlled trial. Antivir Ther 2001 0.77
160 [CBO guidelines 'Antiretroviral therapy in the Netherlands']. Ned Tijdschr Geneeskd 2001 0.77
161 Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis. J Infect Dis 1996 0.76
162 Clinical trials in Asia. AIDS 1998 0.76
163 Implantation of cultured thymic fragments in patients with acquired immunodeficiency syndrome. Arch Intern Med 1986 0.76
164 An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine. AIDS 1998 0.76
165 [Pneumocystis carinii infection during prophylaxis with nebulized pentamidine in a patient with AIDS]. Ned Tijdschr Geneeskd 1991 0.76
166 [Primary infections with human immunodeficiency virus]. Ned Tijdschr Geneeskd 1990 0.76
167 Suppressive therapy for cryptococcal meningitis. N Engl J Med 1992 0.75
168 HIV-1 sensitivity to zidovudine and clinical outcome. Lancet 1992 0.75
169 Serum beta 2-microglobulin levels in asymptomatic HIV-1-infected subjects during long-term zidovudine treatment. Genitourin Med 1991 0.75
170 [Pharmacological treatment of Bell's palsy: favourable effects of prednisolone-based therapy now demonstrated]. Ned Tijdschr Geneeskd 2008 0.75
171 Antiretroviral therapy and clinical trials: what now? Antivir Ther 1996 0.75
172 HIV-1 P24 antigenaemia does not predict time of survival in AIDS patients. Genitourin Med 1990 0.75
173 Cultured human thymus epithelial monolayer cells induce CD4 expression on mononuclear cells of AIDS patients in vitro. Clin Exp Immunol 1986 0.75
174 Longitudinal study on the Quality of Life of symptomatic HIV-infected patients in a trial of zidovudine versus zidovudine and interferon-alpha. AIDS 1993 0.75
175 [Disease symptoms and clinical course in the first 100 patients with AIDS]. Ned Tijdschr Geneeskd 1987 0.75
176 Kaposi's sarcoma and AIDS. Nature 1990 0.75
177 Therapy for cytomegalovirus polyradiculomyelitis in patients with AIDS: treatment with ganciclovir. AIDS 1990 0.75
178 [Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors]. Ned Tijdschr Geneeskd 1998 0.75
179 Gallium-67 lung scintigraphy in patients with acquired immune deficiency syndrome (AIDS). Eur J Respir Dis 1986 0.75
180 Nevirapine plus didanosine: once or twice daily combination? J Acquir Immune Defic Syndr 2000 0.75
181 Thrombocytopenic purpura as first manifestation of human immunodeficiency virus type I (HIV-1) infection. Neth J Med 1990 0.75
182 Serodiagnostic profiles of HIV and HIV pathogenesis in vivo. Haematologia (Budap) 1988 0.75
183 [Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results]. Ned Tijdschr Geneeskd 1998 0.75
184 Effect of high potassium diets on the vascular and renal prostaglandin system in stroke-prone spontaneously hypertensive rats. Prostaglandins Leukot Essent Fatty Acids 1995 0.75
185 Lack of activity of zidovudine in AIDS-associated Kaposi's sarcoma. AIDS 1989 0.75
186 Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1999 0.75
187 A comparison of serum HIV-1 RNA levels as measured by two quantitative assays in zidovudine-treated, asymptomatic, HIV-infected individuals. Antivir Ther 1996 0.75
188 [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. Ned Tijdschr Geneeskd 2001 0.75
189 [Anti-HIV treatment, today and in the near future]. Ned Tijdschr Geneeskd 1992 0.75
190 Non-menstruation associated toxic shock syndrome. Neth J Surg 1985 0.75
191 Effects of recombinant human granulocyte colony-stimulating factor on leucopenia in zidovudine-treated patients with AIDS and AIDS related complex, a phase I/II study. Br J Haematol 1991 0.75
192 [Consensus early treatment with zidovudine]. Ned Tijdschr Geneeskd 1991 0.75
193 [AIDS: new developments. VI. HIV reservoirs during intensive antiretroviral treatment]. Ned Tijdschr Geneeskd 1998 0.75
194 Tolerability and activity of a new recombinant interferon-alpha B/D hybrid in patients with HIV-1 infection. Antivir Ther 1996 0.75
195 AIDS in The Netherlands. Clinical and microbiological data on 36 cases. Neth J Med 1985 0.75
196 Etoposide for epidemic Kaposi's sarcoma: a phase II study. Eur J Cancer Clin Oncol 1988 0.75
197 [A study of hematology questions on the competitive examination of medical residents 1984, 1985 and 1986]. Nouv Rev Fr Hematol 1988 0.75
198 [Early treatment with zidovudine; a turning point in the campaign against AIDS?]. Ned Tijdschr Geneeskd 1989 0.75
199 Additive or sequential nucleoside analogue therapy compared with continued zidovudine monotherapy in human immunodeficiency virus-infected patients with advanced disease does not prolong survival: an observational study. J Infect Dis 1997 0.75
200 Retroviruses et opportunistic infections '99. Antivir Ther 1999 0.75
201 The prevalence of human immunodeficiency virus among pregnant women attending a hospital in the Moungo district, Cameroon. Trop Geogr Med 1989 0.75
202 Summary of the II International Consensus Symposium on Combined Antiviral Therapy and implications for future therapies. Antiviral Res 1997 0.75
203 [Kaposi's sarcoma and other oral manifestations of AIDS]. Ned Tijdschr Tandheelkd 1986 0.75
204 [Coinfection with hepatitis C virus and HIV]. Ned Tijdschr Geneeskd 2003 0.75
205 Quantitative pp65-antigenemia assay for the prediction of human cytomegalovirus disease in HIV-infected patients. AIDS 1999 0.75
206 Playing with evolution requires planning. Antivir Ther 1996 0.75
207 A clinician's perspective: when to start antiretroviral treatment and when to change therapy. J Biol Regul Homeost Agents 1996 0.75
208 Combined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcoma. J Intern Med 1991 0.75
209 Can HIV infection be cured? Antivir Ther 1996 0.75
210 Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996 0.75
211 [J. Slauerhoff. Letters to Hans Feriz]. Ned Tijdschr Geneeskd 1984 0.75
212 Thalidomide for genital ulcer in HIV-positive woman. Lancet 1996 0.75
213 Serologic and immunologic markers in the course of HIV-1 infection. Clin Dermatol 1991 0.75
214 Confirmation of HIV seropositivity: comparison of a novel radioimmunoprecipitation assay to immunoblotting and virus culture. J Med Virol 1988 0.75
215 The first blow is half the battle. Antivir Ther 1997 0.75
216 [Decrease in human immunodeficiency virus antigen levels in the cerebrospinal fluid during zidovudine treatment in patients with AIDS]. Ned Tijdschr Geneeskd 1988 0.75
217 Acute primary HIV-esophagitis. Endoscopy 1990 0.75
218 [Progressive multifocal leukoencephalopathy in AIDS]. Ned Tijdschr Geneeskd 1992 0.75